201 related articles for article (PubMed ID: 23863581)
1. [Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
Abe H; Mafune K; Minamimura K; Abe M; Umemura A; Hirata T
Gan To Kagaku Ryoho; 2013 May; 40(5):601-4. PubMed ID: 23863581
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
[TBL] [Abstract][Full Text] [Related]
3. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
4. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Koyama M; Murata A; Kimura Y; Sakamoto Y; Morohashi H; Kimura N; Gasa F; Sato J; Terui K; Awatsu A; Hakamada K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1069-73. PubMed ID: 20567110
[TBL] [Abstract][Full Text] [Related]
5. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment.
Odabas H; Ozdemir N; Isik M; Abali H; Oksuzoglu B; Kos T; Civelek B; Babacan AN; Dogan U; Zengin N
J BUON; 2011; 16(3):460-3. PubMed ID: 22006750
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older].
Chika N; Ishibashi K; Okada N; Tajima Y; Kumamoto K; Kumagai Y; Baba H; Haga N; Sano M; Ishida H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):857-62. PubMed ID: 25131872
[TBL] [Abstract][Full Text] [Related]
11. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
13. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ueno M; Yamaguchi T
Asia Pac J Clin Oncol; 2014 Dec; 10(4):322-9. PubMed ID: 23915091
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Kuramochi H; Ando M; Itabashi M; Nakajima G; Kawakami K; Hamano M; Hirai E; Yokomizo H; Okuyama R; Araida T; Yoshimatsu K; Kameoka S; Hayashi K
Cancer Chemother Pharmacol; 2017 Mar; 79(3):579-585. PubMed ID: 28213683
[TBL] [Abstract][Full Text] [Related]
18. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Kataoka J; Hori S; Nasu J; Imamine S; Iguchi H
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2249-53. PubMed ID: 18079624
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
